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a b s t r a c t
Urocortin (UCN), a 40 amino acid peptide, is a corticotrophin-releasing hormone (CRH)-related peptide.
The biological actions of CRH family peptides are mediated via two types of G protein-coupled receptors,
CRH type 1 receptor (CRHR1) and CRH type 2 receptor (CRHR2). The aim of the present study was to
investigate the expression of UCN, CRHR1 and CRHR2 by immunohistochemistry, western blot and
real-time RT-PCR in the bovine adrenal gland to clarify the mechanisms of the intra-adrenal CRH-based
regulatory system. The results showed that UCN, CRHR1 and CRHR2 were expressed in both the cortex
and medulla. Speciﬁcally, UCN-immunoreactivity (IR) was distributed in the outer part of the zona fascic-
ulata and in the zona reticularis of the cortex and in the medulla. UCN and CRHR2 mRNA expression levels
were higher in the cortex than in the medulla, while CRHR1 mRNA levels were undetectable in the cortex.
These results suggest that UCN, CRHR1 and CRHR2 are expressed in the bovine adrenal gland and that
UCN might play a role in the intra-adrenal CRH-based regulatory system through an autocrine
mechanism.
 2011 Elsevier Inc. All rights reserved.
1. Introduction
Urocortin 1 or urocortin (UCN), a 40-amino acid peptide, is a
corticotrophin-releasing hormone (CRH)-related peptide. UCN is
the ﬁrst CRH-related neuropeptide to be identiﬁed from a screen
using an urotensin probe in a rat midbrain library and subse-
quently cloned in the human [40,9,11,7,42,43].
The ﬁrst component of the name ‘‘Urocortin’’ is derived from
the homology UCN exhibits to the teleost hormone urotensin I,
while the second component stems from the homology to CRH. In-
deed, UCN shares 63% identity to teleost ﬁsh urotensin I, 45% iden-
tity to rat/human CRH and 35% identity to a 40-amino acid non-
mammalian CRH-like peptide, sauvagine. Like CRH, UCN can stim-
ulate ACTH production from anterior pituitary corticotrophs
in vitro and in vivo [1]. UCN is more potent than CRH with regard
to other biological effects, including suppression of appetite, but
is less potent in generating anxiety. A few years after the identiﬁ-
cation of UCN, two additional mammalian CRH-like peptides were
isolated. Urocortin 2 (UCN2; stresscopin-related peptide) is a 38-
amino acid peptide with an amidated C-terminus that was ﬁrst
predicted in mouse from a gene encoding a 112-amino acid protein
[32,13,42]. Human urocortin 3 (UCN3; stresscopin) was identiﬁed
later and found to have high identity (>80%) to UCN2
[20,37,33,16]. The biological effects of CRH and UCNs are mediated
by two distinct receptors, CRH receptor type 1 (CRHR1) and 2
(CRHR2), which belong to the G protein-coupled receptor super-
family of brain-gut neuropeptides [28,41,5,29]. Two separate genes
encode the CRH receptors [5]. CRHR1, a 415-amino acid protein,
exhibits high afﬁnity towards CRH and UCN, but low afﬁnity to-
wards UCN2 and no afﬁnity towards UCN3. CRHR1 is primarily ex-
pressed in the CNS and the anterior pituitary. The CRHR2 receptor
shares 70% sequence identity with CRHR1 and is expressed primar-
ily in extra-CNS sites. The CRHR2 receptors exhibit high afﬁnity to-
wards UCNs and no afﬁnity towards CRH. Activation of CRHR2
suppresses multiple metabolic functions, including feeding in
fasted mice [2], heat-induced oedema and gastric emptying [19].
The presence of UCN and CRH has previously been demon-
strated in the rat adrenal gland [22,27]. Strong expression of UCN
has been demonstrated throughout the mammalian adrenal me-
dulla and in the cortical fasciculate and glomerulosa zones, but
weak expression has been detected in the reticularis zone [8].
CRHR1 and CRHR2 were clearly expressed in the medulla, weakly
expressed in the cortical fasciculate and glomerulosa zones and
barely expressed in the reticularis zone [12,8]. These results sug-
gest that UCNs may play important roles in physiological adrenal
functions, particularly in the regulation of adrenal hormone
synthesis.
In the bovine, CRH-IR has been demonstrated to be distributed
in the adrenal medulla [23]. In addition, CRH binding sites have
been demonstrated in cultured chromafﬁn cells [6]. From a
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physiological perspective, CRH has been proposed to enhance the
steroidogenic response of the adrenal cortex to ACTH [10]. More-
over, exogenous CRH has been demonstrated to enhance adrenal
steroidogenesis in hypophysectomised calves [18], implying that
the effect of the CRH is direct and not via ACTH. To our knowledge,
little or no data are available regarding the presence and putative
roles of UCNs in the adrenal gland of the bovine.
The aim of the present study was to investigate the expression
of UCN, CRHR1 and CRHR2 in the bovine adrenal gland to clarify
the mechanisms of the intra-adrenal CRH-based regulatory system.
For this purpose, we performed Western blot and immunohisto-
chemistry to study the presence and distribution of these proteins
and real-time RT-PCR to evaluate mRNA expression levels in both
the cortex and medulla.
2. Methods
2.1. Animals and tissue collection
This study was performed using six adult (age ranged from 1.5
to 5 years) healthy animals of both sexes coming from the same
farm located in Southern Italy. The animals were bred in natural
environmental conditions and were fed hay and concentrate.
Water was available continuously. The animals were sacriﬁced in
a public slaughterhouse according to the current Italian animal
care protocols. Bovine hypothalamus (as a positive control) and
adrenal glands from these animals were collected in the same
day. For western blot and RT-PCR analyses, adrenocortical tissue
was dissected from medullary tissue and immediately frozen on
dry ice and stored at 80 C. For immunohistochemical studies,
fresh segments of adrenal gland were immediately ﬁxed.
2.2. Western blot analysis
Frozen tissues were homogenised in a homogenisation buffer
(50 mM Tris HCl, pH 7.00; 150 mM NaCl; 2% Triton; 5 mM EDTA;
10 mg/ml leupeptin; 0.1 U/ml aprotinin; 1 mM PMSF) using an Ul-
tra-Turrax homogeniser and centrifuged at 16,000g for 20 min at
4 C. Aliquots of the supernatant were subjected to electrophoresis
on 12% and 18% sodium dodecyl sulphate (SDS)–polyacrylamide
(Bio-Rad, Hercules, CA, USA) gels. After electrophoresis, the gel
was transferred to nitrocellulose using a semi-dry apparatus
(Bio-Rad, Hercules, CA, USA) according to the manufacturer’s
instructions. The membrane was incubated for 1 h at 42 C in 5%
bovine serum albumin (BSA; Sigma, St. Louis, MO, USA) in TBST
(150 mM NaCl; 20 mM Tris HCl, pH 7.4; 0.3% Tween-20), washed
with TBST and incubated for 2 h at RT in the antisera diluted
1:500 in TBST containing 1% BSA. The following antisera were
used: polyclonal goat anti-urocortin (sc-1825, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA), anti-CRHR1 (sc-12383; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and anti-CRHR2 (sc-1826;
Santa Cruz Biotechnology, CA, USA). To conﬁrm speciﬁcity, the
membranes were also incubated in the presence of primary anti-
body pre-absorbed (pre-absorption control) with the speciﬁc
immunising peptides. For pre-absorption, urocortin, CRHR1 and
CRHR2 antibodies diluted 1:500 (0.4 lg/ml) were incubated with
a 10-fold (by weight) excess of blocking peptide (UCN peptide
sc-1825P, CRHR1 peptide sc-12383P and CRHR2 peptide sc-
1826P; synthesised by Santa Cruz Biotechnology, Inc., 2145 Dela-
ware Avenue Santa Cruz, CA 95060, USA; purity: >95%) in a small
volume (500 ll) of TBS overnight at 4 C before being applied to
the blots instead of the primary antibody alone. The membrane
was washed three times with TBST, incubated for 1 h with anti-
goat IgG peroxidase conjugate (Vector Laboratories, Burlingame,
CA, USA) diluted 1:2000 in TBST–1% BSA and washed three times
with TBST. Proteins were visualised by an enhanced chemilumi-
nescence kit (Amersham, Buckinghamshire, UK). Marker proteins
(coloured protein molecular weight markers; Rainbow, Amer-
sham) were used to estimate the molecular weight of each band.
2.3. Immunohistochemistry
Fresh segments of adrenal gland were ﬁxed by immersion in
Bouin’s ﬁxative (6–24 h), processed for parafﬁn embedding in a
vacuum and cut at a thickness of 5–7 lm. The avidin–biotin–per-
oxidase complex (ABC) method was performed using the Vecta-
stain ABC kit (Vector Laboratories, Burlingame, CA, USA). Parafﬁn
sections were deparafﬁnised in xylene and hydrated in a graded
series of ethanol solutions. After the quenching of endogenous per-
oxidase activity in water containing 3% hydrogen peroxide for
30 min, nonspeciﬁc binding was blocked by treatment with 1.5%
normal rabbit serum (Vector) in 0.01 M phosphate-buffered saline
(PBS; pH 7.2) for 30 min. Polyclonal goat anti-urocortin (sc-1825),
anti-CRHR1 (sc-12383) and anti-CRHR2 (sc-1826) were singularly
applied to the sections at a dilution of 1:500, and each specimen
was incubated in a moist chamber overnight at 4 C. After the sec-
tions had been washed three times in PBS, biotinylated anti-rabbit
IgG (Vector) was applied at a dilution of 1:200. The sections were
again incubated for 30 min at room temperature. Freshly prepared
ABC reagent (Vector) was applied and incubated for 30 min after
three washes in PBS. The localisation of the immunoreactions
was visualised by incubating the sections for 5 min in freshly pre-
pared diaminobenzidine–nickel solution (Vector). The speciﬁcity of
the immunoreactions was tested by replacing the primary anti-
body with buffer. No immunoreaction was detected in control
tests. The speciﬁcity of the primary antibodies was tested by
absorption with excess homologous antigen peptide as described
above for the Western blot (UCN peptide sc-1825P, CRHR1 peptide
sc-12383P and CRHR2 peptide sc-1826P; Santa Cruz Biotechnol-
Fig. 1. UCN, CRHR1 and CRHR2 expression by western blot analysis. Lane 1: adrenal
cortex tissue; lane 2: adrenal medulla tissue; lane 3: UCN synthetic peptide
(100 ng/lane); molecular weight markers are expressed in kDa. No immunoreaction
was observed in the blots tested with pre-adsorbed antibodies.
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ogy) (Fig. 2). The speciﬁcity of the anti-CRHR1 and anti-CRHR2
antisera was tested in dot-blot assays. To perform dot-blot analy-
sis, we spotted a serial dilution of tissue homogenate onto a nitro-
cellulose membrane and allowed it to air dry. The membrane was
then treated in a manner similar to that used in the Western blot
analysis.
The slides were observed using a Leica DMRA2 microscope (Lei-
ca Microsystems, Wetzlar, Germany).
2.4. RNA extraction, cDNA synthesis, RT-PCR and sequencing
Samples of the adrenal cortex and medulla were individually
homogenised in ice-cold TRI-Reagent (Sigma, St. Louis, MO, USA)
using an Ultra-Turrax homogeniser. After chloroform extraction
and isopropyl alcohol precipitation, RNA was dissolved in RNA-
ase-free DEPC water. Total RNA was measured with an Eppendorf
Biophotometer (Eppendorf AG, Basel, Switzerland). For cDNA syn-
thesis, 1 lg of total RNA was retro-transcribed with the High
Capacity cDNA Reverse Transcription kit (Applied Biosystems,
USA) and random hexamers as primers. For PCR reactions, speciﬁc
primers for bovine urocortin and CRH-R1 were designed from the
published gene sequences (Bos taurus urocortin mRNA, Genbank
accession number NM_001032301; B. taurus CRHR1, mRNA, Gen-
bank, NM_174287) using the Primer Express™ software (PE Ap-
plied Biosystems). Speciﬁc primers for bovine CRH-R2 were
designed generating a multiple sequence alignment based on the
published sequences in GenBank from Mus musculus CRHR2 mRNA
Genbank accession number NM_009953, Homo sapiens CRHR2,
mRNA Genbank accession number NM_001883, Rattus norvegicus
CRHR2, mRNA Genbank accession number NM_022714 and prim-
ers were designed in conserved regions of the nucleotide sequence.
The sense and anti-sense urocortin primers used were 50-CGA CCC
TCC CCT GTC CAT-30 and 50-TTC CTG TCG CTC ACG TCT CA-30,
respectively, which amplify a 200-bp fragment; the sense and
anti-sense CRH-R1 primers were 50-TAC GAC AAT GAG AAG TGC
TGG TTT-30 and 50-GGC ACG GAT TGA GTG CTT GT-30, respectively,
which amplify a 409-bp fragment; the sense and anti-sense CRH-
R2 primers were 50-GCT GTC TGC GGA ACG TGA TT-30 and 50-
CGA AGT AGT TGA AGA TGG TGG TGA T-30, respectively, which am-
plify a 200-bp fragment.
The PCR cycle conditions were as follows: 94 C (30 s), 60 C
(30 s), 72 C (1 min) for 35 cycles; 72 C (5 min). The PCR products
of bovine urocortin, CRHR1 and CRHR2 were puriﬁed using GFX
PCR DNA and Gel Puriﬁcation Kit (code 28-9034-70, GE Healthcare)
and sequenced.
2.5. Real-time RT-PCR
The sense and anti-sense urocortin primers used were 50-CGA
CCC TCC CCT GTC CAT-30 and 50-TTC CTG TCG CTC ACG TCT CA-
30, respectively, which amplify a 200-bp fragment. The sense and
anti-sense CRH-R2 primers were 50-GCT GTC TGC GGA ACG TGA
TT-30 and 50-CGA AGT AGT TGA AGA TGG TGG TGA T-30, respec-
tively, which amplify a 200-bp fragment. The sense and anti-sense
beta-Actin primers were 50-CAG CTC CTC CCT GGA GAA GA-30 and
50-CTG CTT GCT GAT CCA CAT CTG-30, which amplify a 398-bp
fragment.
The PCR conditions were 50 C for 2 min and 94 C for 10 min,
followed by 40 cycles of 94 C for 15 s and 60 C for 1 min. The
PCR reactions contained 1 ll cDNA (40 ng/well) and 24 ll of SYBR
Green Master Mix (Applied Biosystems) containing speciﬁc prim-
ers. A sample without cDNA template was used to verify that the
master mix was free from contaminants. The samples were ana-
lysed in triplicate.
The b-Actin gene was also ampliﬁed in separate tubes under the
same conditions to serve as an active endogenous reference to nor-
malise quantiﬁcation of the mRNA target. Real-time PCR reactions
for the target and reference genes were run in the same RT reac-
tion. Real-time detection was performed on an ABIPRISM 7300 Se-
quence Detection System (Applied Biosystems), and data from
SYBR Green I PCR amplicons were collected with ABI 7300 System
SDS Software. The ﬂuorescence baseline signal and threshold were
set manually for each detector (UCN, CRHR2, beta-Actin), generat-
ing a threshold cycle (Ct) for each sample. An ampliﬁcation plot
graphically displayed the ﬂuorescence detected over the number
of cycles that were performed.
Standard curves for both targets and the endogenous reference
gene, created on the basis of the linear relationship between the Ct
value and the logarithm of the starting amount of cDNA, showed
acceptable slope values (between 3.8 and 3.3). Standard curves
Fig. 2. Representative controls for immunohistochemistry experiments in the bovine adrenal gland. (a–f) Sections of the zona fasciculata of the adrenal cortex. (a) UCN-IR; (b)
CRHR1-IR; (c) CRHR2-IR. The staining disappeared when the primary antibodies against (d) UCN, (e) CRHR1 and (f) CRHR2 were pre-adsorbed with synthetic peptides.
Bar = 50 micron.
418 C. Squillacioti et al. / General and Comparative Endocrinology 172 (2011) 416–422
Author's personal copy
were obtained by using serial dilutions of sample cDNA (1:2, 1:4,
1:8, 1:16 and 1:32).
The relative quantiﬁcation method 2-[Delta][Delta] Ct (2-delta
delta Ct) (DDCt) was used for normalisation of gene expression
[21,14,44]. Before using the DDCt method for relative quantiﬁca-
tion (comparative method), a validation experiment was required
to demonstrate that the efﬁciencies of the target ampliﬁcation
and of the reference ampliﬁcation were almost equal. All PCR efﬁ-
ciencies were measured and found to be adequate (slope < 0.1).
The DDCt method used in this study has previously been described
[36]. Brieﬂy, the difference between Ct values was calculated for
each mRNA by taking the mean Ct of triplicate reactions and sub-
tracting the mean Ct of triplicate reactions for the reference RNA
measured in an aliquot from the same RT reaction (DCt = Ct (target
gene)  Ct (reference gene)). All samples were then normalised to
the DCt value of a calibrator sample to obtain a DDCt value (DCt
(target)  DCt (calibrator)). Adrenal cortex was used as the calibra-
tor sample in the comparison with adrenal medulla. Dissociation
melt curves conﬁrmed the speciﬁc ampliﬁcation of the cDNA target
and the absence of nonspeciﬁc products. The results are repre-
sented as mean (±SEM) of triplicate determinations for each tissue
and from each experimental animal. For statistical analyses, the
data were expressed as the mean ± standard error. Signiﬁcant dif-
ferences in UCN and CRHR2 mRNA levels between the calibrator
sample (adrenal cortex) vs. adrenal medulla were determined
using Student’s t-test for independent samples. The level of statis-
tical signiﬁcance was set at p < 0.05 for all.
3. Results
3.1. Western blot
The results of the western blot analysis are shown in Fig. 1. Tis-
sue extracts of the cortex and medulla of the bovine adrenal gland
reacted with the anti-UCN, -CRHR1 and -CRHR2 antibodies. The
cortex and medulla tissue extracts and the synthetic peptide UCN
reacted with the anti-UCN antibody (Fig. 1). The antiserum recog-
nised one major protein band of approximately 16 kDa from
homogenates and one protein band of approximately 6.5 kDa from
the synthetic peptide. The cortex and medulla tissue extracts also
reacted with the anti-CRHR1 and anti-CRHR2 antibodies (Fig. 1).
The antisera recognised one protein band measuring approxi-
mately 55 kDa from the homogenates.
3.2. Immunohistochemistry
In the bovine adrenal gland, UCN-immunoreactivity (IR) was
found both in the cortex and in the medulla (Fig. 3a). In the cortex,
UCN-IR was distributed in the zona fasciculata (Fig. 3b) and in the
zona reticularis (Fig. 3e). In the zona fasciculata, immunoreactivity
was primarily detected in the fasciculate cells located in the outer
portion underneath the zona glomerulosa. In the zona reticularis,
only some scattered cells were immunoreactive. In the adrenal me-
dulla, almost all of the medullary cells were positive (Fig. 3h). The
distribution of CRHR1- (Fig. 3c, f and i) and CRHR2- IR (Fig. 3d, g
and l) was similar to that of UCN-IR.
3.3. RT-PCR and real time RT-PCR
RT-PCR experiments demonstrated that UCN and CRHR2 were
expressed in both the cortex and medulla, while CRHR1 was ex-
pressed only in the medulla (Fig. 4a). Real-time RT-PCR experi-
ments conﬁrmed that UCN and CRHR2 were expressed in both
the bovine adrenal cortex and medulla. The levels of UCN and
CRHR2 mRNA expression were higher in the cortex than in the me-
dulla (Fig. 4b).
4. Discussion
The results of the present study revealed the presence of UCN,
CRHR1 and CRHR2 mRNA and protein in the bovine adrenal gland
using different experimental approaches. Speciﬁcally, western blot
analysis was used to study the presence of UCN and its receptors in
the bovine adrenal cortex and medulla. Immunohistochemical
studies were performed to evaluate the distribution and localisa-
tion of these proteins throughout the bovine adrenal gland, and
RT-PCR and real-time RT-PCR analyses were performed to reveal
and quantify the mRNA levels of UCN, CRHR1 and CRHR2. The util-
isation of multiple experimental approaches allowed us to obtain
complementary information regarding the expression and the
putative roles of UCN, CRHR1 and CRHR2 in the bovine adrenal
gland.
Western blot analysis showed that the anti-mammalian UCN
antiserum used in the present study recognised a protein band
with a molecular weight of approximately 16 kDa in the bovine
adrenal gland. This protein is comparable to the mammalian UCN
precursor, which is a 122-amino acid protein [40,9]. In addition,
the antisera used against CRHR1 and CRHR2 recognised protein
bands with molecular weights of approximately 55 kDa. These pro-
teins are comparable to the mammalian CRH-Receptors [29,5].
The results of the present study showed that in the bovine adre-
nal cortex, UCN-, CRHR1- and CRHR2-IRs were distributed in the
zona fasciculata and zona reticularis, but not in the zona glomerulosa.
These results agree only in part with those reported in human and
rat adrenal cortex, in which immunoreactivity to these proteins is
expressed in all three adrenocortical zones, with a stronger inten-
sity in the zona glomerulosa and zona fasciculata than in the zona
reticularis [7,23,11]. These discrepancies may reﬂect interspecies
variations in the distribution and consequently, the function, of
the UCN/CRHRs system throughout the mammalian adrenal cortex.
Our ﬁndings suggest that UCN affects steroid secretion via
CRHRs preferentially in an autocrine manner. Several reports have
indicated that CRH and its related peptides play a role in the regu-
lation of adrenal hormone synthesis [7,11] and affect the adrenal
glands directly as local modulators of adrenal functions [38,39].
CRH and UCN stimulate cortisol production by human foetal adre-
nocortical cells in vitro [34,35] and cortisol and aldosterone secre-
tion in human adrenal H395R cells [17]. In the bovine, exogenous
CRH has been reported to enhance adrenal steroidogenesis in
hypophysectomised calves [16], implying that the effect of the
CRH is direct and does not act via ACTH. Because the immunoreac-
tivity to UCN and its receptors was not detected in the zona glome-
rulosa, one can hypothesise that the UCN system inﬂuences cortisol
[34] and sexual steroid [30,31,34,35] rather than aldosterone syn-
thesis in the bovine adrenal gland.
The results regarding the distribution of UCN-, CRHR1- and
CRHR2-IRs in the medulla are in accordance with previous reports
that have described the expression of UCN-, CRHR1- and CRHR2-
IRs in the mouse, human and rat adrenal glands [7,23,11,38].
CRH peptides also affect de novo catecholamine synthesis. More
speciﬁcally, UCN induces tyrosine hydroxylase (TH) expression via
cAMP in rat adrenomedullary PC12 cells [24], while UCN2 induces
TH phosphorylation via the PKA-Erk1/2 pathway [25,26]. Both
CRHR1 and CRHR2 agonists have been observed to induce de novo
catecholamine synthesis via induction of TH [8]. Thus, prolonged
exposure of the adrenal glands to stress peptides (a condition that
occurs during chronic stress) may result in increased TH expres-
sion levels, leading to the elevation of stored adrenaline in the
secretory vesicles of adrenal medullary cells, thus augmenting
the magnitude of the catecholaminergic response to stressors [8].
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RT-PCR experiments revealed that UCN, CRHR1 and CRHR2
mRNAs were expressed in the bovine adrenal gland, thus conﬁrm-
ing the immunohistochemical staining data. These results were in
accordance with previous studies in which UCN, CRHR1 and CRHR2
mRNAs were found in both the human and murine adrenal glands
[24,12]. However, in the present study, RT-PCR analysis revealed
that CRHR1 mRNA was present only in the medulla, while immu-
nohistochemistry and western blot analysis demonstrated that
CRHR1 protein was present in both the cortex and medulla. This
discrepancy is probably due to the very low levels of CRHR1 mRNA
expression.
Real-time RT-PCR experiments revealed that UCN and CRHR2
mRNA levels were higher in the cortex than in the medulla. Until
now, no data have been available regarding the quantitative distri-
bution of UCN and CRHR2 transcripts in the mammalian adrenal
gland. This result suggests that the activity of the urocortinergic
Fig. 3. Distribution of the UCN-, CRHR1- and CRHR2-immunoreactivities in the bovine adrenal gland. (a) UCN-IR was distributed in the zona fasciculata and zona reticularis of
the adrenal cortex and in the medulla. ZG: zona glomerulosa; ZF: zona fasciculata; ZR: zona reticularis; M: medulla; bar = 100 lm. (b) Higher magniﬁcation of the zona
fasciculata shows UCN-immunoreactive cells in this zone (arrows); bar = 25 lm. (c) Higher magniﬁcation of the zona fasciculata shows CRHR1-immunoreactive cells in this
zone (arrows); bar = 25 lm. (d) Higher magniﬁcation of the zona fasciculata shows CRHR2-immunoreactive cells in this zone; bar = 25 lm. (e) Higher magniﬁcation of the
zona reticularis shows UCN-immunoreactive cells in this zone (arrows); bar = 25 lm. (f) Higher magniﬁcation of the zona reticularis shows CRHR1-immunoreactive cells in this
zone (arrows); bar = 25 lm. (g) Higher magniﬁcation of the zona reticularis shows CRHR2-immunoreactive cells in this zone (arrows); bar = 25 lm. (h) Higher magniﬁcation
of the medulla shows that the great majority of the cells were UCN-positive in this zone; bar = 25 lm. (i) Higher magniﬁcation of the medulla shows that the great majority of
the cells were CRHR1-positive in this zone; bar = 25 lm. (l) Higher magniﬁcation of the medulla shows that the great majority of the cells were UCN-positive in this zone;
bar = 25 lm.
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system in the adrenal gland is higher in the cortex than in the
medulla.
CRH peptides in the adrenals may affect catecholamine and ste-
roid synthesis under a complex mechanism that depends on the li-
gand concentration and receptor availability. The concentration of
bioavailable CRH peptides is known to be modulated by the CRH-
binding protein (CRH-BP), a 37 kDa protein ﬁrst isolated in the hu-
man plasma [3] and subsequently discovered in the brain [30] and
in several other tissues, including the adrenal gland [4]. CRH-BP
binds to both CRH and UCN with high afﬁnity and to UCN2 with
intermediate afﬁnity, but does not appreciably bind to UCN3
[15]. CRH-BP has higher afﬁnity for CRF and UCN than CRHR2, thus
CRH-BP is generally considered an antagonist of this receptor. CRH-
BP seems to limit the activity of UCN [30,34] and, moreover, to in-
crease the half-life of CRH or other CRH-like ligands by protecting
them from degradation and delivering the ligand to receptors in
the target tissue (thus enhancing activity). Other CRHR2 ligands,
such as UCN2 and UCN3, probably interact with this receptor to
regulate adrenal functions. In addition to UCN1, UCN2 and UCN3
have also been demonstrated to be involved in the intra-adrenal
CRH-based regulatory system [8,12,38]. A complex intramedullary
UCN1–UCN2/CRH receptor system exists in the human and rat
adrenal gland that controls catecholamine synthesis and secretion
[8]. In addition, UCN3 is expressed in the human adrenal gland,
where it may play a role by binding to CRHR2 in the regulation
of the adrenal steroidogenesis and may therefore exert vasodilator
effects on the adrenal circulation [12,37,38].
In conclusion, these results suggest that UCN, CRHR1 and
CRHR2 are expressed in the bovine adrenal gland. The levels of
CRHR2 and UCN mRNAs are higher in the adrenal cortex. These
data suggest that UCN plays a major role in the intra-adrenal
CRH-based regulatory system through an autocrine mechanism
that preferentially acts via CRHR2.
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